Lionheart Health, a regenerative health and longevity technology company, has announced a strategic partnership with Rejuvant, developer of the patented, sustained-release Calcium alpha-ketoglutarate (CaAKG) supplementation, as part of Lionheart Health’s participation in the XPRIZE Healthspan Semi-Finals. Lionheart Health was selected as a top 40 semi-finalist out of more than 600 entries in spring 2025.
Under the collaboration, Rejuvant’s CaAKG supplement—associated with peer-reviewed research demonstrating improvements in biological age markers—has been designated a mandatory core component of the Lionheart KLOTHO-UP™ Study and the broader Lionheart Klotho Wellness Program, both central to Lionheart’s XPRIZE Healthspan initiative.
The Lionheart KLOTHO-UP™ Study integrates Rejuvant’s CaAKG supplementation within a multi-modal healthspan optimization framework designed to evaluate coordinated improvements across muscle, metabolic, immune, cardiovascular, and brain health domains. In addition to Rejuvant CaAKG, all study participants receive SNiP Nutrition™ personalized supplements, customized based on genetic and biomarker profiles; targeted Klotho-focused supplementation; and Lionheart Health’s BodStim™ bioelectric exercise platform, which delivers Klotho- and follistatin-elevating electrical muscle stimulation–enhanced exercise sessions (1 hour, 2–3 times per week).
All enrollees in the KLOTHO-UP™ Study and Klotho Wellness Program undergo an extensive testing and evaluation protocol at baseline, 3 months, 6 months, and 12 months, including a 461-biomarker comprehensive blood panel including klotho levels; AI-enhanced full-body MRI, with targeted organ and tissue analysis (optional); muscle health assessments (grip strength, 6-minute walk, muscle mass index, gait speed); gut health, immunity strength, and microbiome assessment; breathing and sleep analysis (optional); stress and inflammation profiling, including cortisol measurement (optional); blood sugar and metabolic regulation analysis; vascular and calcification assessment (optional); joint health and mobility evaluation (optional); sexual health assessment (optional); vision and hearing evaluation (optional); and brain health testing, including cognition, memory, and mood metrics. This longitudinal design enables objective tracking of functional healthspan changes over time rather than reliance on single-endpoint or short-duration outcomes.
“Rejuvant’s CaAKG platform represents one of the most rigorously studied nutritional interventions in the biological aging space,” said a spokesperson for Lionheart Health. “By making CaAKG a mandatory core component of our XPRIZE Healthspan protocol, we are anchoring our program in validated metabolic biology while layering in advanced bioelectric, Klotho-focused, and personalized technologies.” A representative from Rejuvant added, “We are excited to partner with Lionheart Health in the XPRIZE Healthspan Semi-Finals. This collaboration allows CaAKG supplementation to be evaluated within one of the most comprehensive, biomarker-driven healthspan programs ever assembled.”
Lionheart Health is a regenerative health and longevity technology company developing integrated platforms focused on bioelectric control of regenerative protein expressions, Klotho-centric biology, personalized nutrition, and advanced diagnostics. The company is an XPRIZE Healthspan Semi-Finalist and has received multiple recognitions, including an Abbvie Allergan Innovation Award and being named Stimulator Developer of the Year 2025 by Medtech Outlook Magazine. Rejuvant is a longevity biotechnology company developing clinically researched and patented CaAKG supplements aimed at supporting healthy aging.
